Q&A with Schenk AccuRate's Chad Lorensen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Schenk AccuRate's Chad Lorensen
Lorensen discusses client demands and industry trends.

Pharmaceutical Technology
Volume 34, Issue 5, pp. 86

Q & A with
Chad Lorensen, pharmaceutical industry business-development manager of Schenck AccuRate



PharmTech:
What is the biggest industry challenge you're now facing?

Lorensen
The development of continuous manufacturing processes. We are monitoring, helping where we can, and working with companies in the pharmaceutical industry who are studying continuous manufacturing processes for solid dosage products. Our core products have the strengths that provide value for this type of manufacturing process.

PharmTech:
How do you stay abreast of new developments in the industry?

Lorensen
Schenck stays abreast of the latest industry developments through regular communication with our customers, developing strong working relationships with other pharmaceutical-industry equipment manufacturers, and by participating in research consortiums at various universities. Further information is gathered by reviewing various pharmaceutical periodicals and attending trade show exhibitions. In addition, Schenck is a global company, and each of its offices can share ideas with other Schenck locations throughout the world.

PharmTech:
Do you see a new industry trend emerging?

Lorensen
We are looking forward to the pharmaceutical industry's acceptance of continuous mixing, granulation, and hot-melt extrusion.

PharmTech:
What is the most common demand your clients are currently making of you?

Lorensen
The most common request is to provide equipment to customers' sites for trials and experiments made in conjunction with other types of continuous processing equipment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here